George Mskhalaya
Internal medicineUrologyEndocrinologyRandomized controlled trialPediatricsPlaceboProstateKlinefelter syndromeType 2 diabetesAge of onsetSexual dysfunctionTestosterone (patch)Erectile dysfunctionBody mass indexMetabolic syndromeTestosterone GelGynecologyDouble blindLate onsetDiagnosis treatmentTestosterone deficiencyDepressive symptomsPhysiologyFamily medicineTestosteroneMedicine
25Publications
6H-index
706Citations
Publications 25
Newest
#1George MskhalayaH-Index: 6
#2Yulia TishovaH-Index: 1
Last. Svetlana KalinchenkoH-Index: 6
view all 4 authors...
The increasing prevalence of obesity, in particular in young patients, represents a growing clinical and health-care cost problem. Young adulthood obesity strongly increases the risk of type 2 diabetes (T2DM),
Source
Source
Last. Yulia TishovaH-Index: 1
view all 4 authors...
«Old» oral forms of methylated testosterone (methyltestosterone, fluoxymesterone) should not be used due to their high hepatotoxicity. Modern oral forms of testosterone (testosterone undecanoate), according to their pharmacodynamic properties (absorbed from the intestine via the lymphatic route, thus circumventing the first-pass inactivation by the liver), have a good hepatic safety profile. The pharmacokinetic characteristics of oral testosterone undecanoate do not allow maintaining an adequate...
Source
#1Abraham Morgentaler (Harvard University)H-Index: 55
view all 33 authors...
Conference on the development of the international expert consensus to address frequently asked questions related to a medical condition of testosterone deficiency (TD, male hypogonadism) and testosterone therapy was held in Prague (Czech Republic) on October 1, 2015. The included experts were representatives from a variety of medical specialties, including urology, endocrinology, diabetology, internal medicine, as well as representatives of basic medical sciences. An international team of exper...
Source
#1Abraham Morgentaler (Harvard University)H-Index: 55
#2Michael ZitzmannH-Index: 52
Last. Luiz Otavio TorresH-Index: 16
view all 17 authors...
To address widespread concerns regarding the medical condition of testosterone (T) deficiency (TD) (male hypogonadism) and its treatment with T therapy, an international expert consensus conference was convened in Prague, Czech Republic, on October 1, 2015. Experts included a broad range of medical specialties including urology, endocrinology, diabetology, internal medicine, and basic science research. A representative from the European Medicines Agency participated in a nonvoting capacity. Nine...
58 CitationsSource
#1Bruno Lunenfeld (BIU: Bar-Ilan University)H-Index: 43
#2George MskhalayaH-Index: 6
Last. Abraham Morgentaler (Harvard University)H-Index: 55
view all 7 authors...
Hypogonadism or Testosterone Deficiency (TD) in adult men as defined by low levels of serum testosterone accompanied by characteristic symptoms and/or signs as detailed further on can be found in long-recognized clinical entities such as Klinefelter syndrome, Kallmann syndrome, pituitary or testicular disorders, as well as in men with idiopathic, metabolic or iatrogenic conditions that result in testosterone deficiency. These recommendations do not encompass the full range of pathologies leading...
174 CitationsSource
#1Bruno Lunenfeld (BIU: Bar-Ilan University)H-Index: 43
#2George MskhalayaH-Index: 6
Last. Yulia TishovaH-Index: 1
view all 4 authors...
AbstractRecommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men were first published by ISSAM in 2002 In 2005, and, in 2008, updated recommendations were published in the International Journal of Andrology, the Journal of Andrology, the Aging Male and European Urology. Towards discussions at the next ISSAM/ESSAM meeting in Moscow, 29 November 2013, we suggest the following update.
36 CitationsSource
#2Yuliya TishovaH-Index: 4
Last. Farid Saad (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 47
view all 6 authors...
Summary Objective Men with the metabolic syndrome (MetS) have low plasma testosterone (T) levels. The aim of this study was to establish whether the normalization of plasma T improves the features of the MetS. Design A randomized, placebo-controlled, double-blinded, phase III trial of 184 men suffering from both the MetS and hypogonadism. Patients One hundred and eighty-four men, aged 35–70, with the MetS and hypogonadism (baseline total T level <12·0 nm or calculated free T level <225 pm.), rec...
367 CitationsSource
#1Erik J. Giltay (LUMC: Leiden University Medical Center)H-Index: 70
#2Yuliya TishovaH-Index: 4
Last. Svetlana KalinchenkoH-Index: 6
view all 6 authors...
ABSTRACT Introduction Low testosterone levels in men are associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality, and sexual dysfunction. Aim To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS. Main Outcome Measures The Beck Depression Inventory (BDI-IA), Aging Males' Symptoms (AMS) scale, and International Index of Erectile Function 5-item (IIEF-5) sca...
144 CitationsSource
#1Erik J. GiltayH-Index: 70
#2Yuliya TishovaH-Index: 4
Last. Svetlana KalinchenkoH-Index: 6
view all 6 authors...